Streetbeat News

Revenues

MRNS

Marinus Pharmaceuticals forecasts FY23 revenues for Ztalmy (Ganaxolone) to be between $19.5M-$19.7M, with Q4 revenues estimated at $6.5M-$6.7M.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:08 pm

ENTA

Enanta Pharmaceuticals announced its plans for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference, including an update on its pipeline. The company is expanding into immunology with a new oral KIT inhibitor program for CSU, aiming for development candidate selection in 2024. Enanta also expects topline data from a Phase 2 study of Zelicapavir (EDP-938) for RSV treatment in 3Q 2024, and challenge study data for EDP-323, another RSV treatment, in the same quarter.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:07 pm

ACET

Adicet Bio, Inc. (NASDAQ:ACET) aims to advance its pipeline of allogeneic gamma delta T cell therapies in 2024, focusing on oncology and autoimmune diseases. The FDA cleared an IND for ADI-001 in lupus nephritis, with a Phase 1 trial expected in Q2 2024. In hematologic malignancies, ADI-001 showed promising results in MCL patients, and a clinical update is anticipated in the second half of 2024. The company also plans to file an IND for ADI-270, targeting renal cell carcinoma, in Q2 2024. Adicet Bio's cash runway is projected to last into the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:04 pm

MBLY

Mobileye has provided its FY24 outlook, projecting revenues of $1.830B-$1.960B, which is significantly lower than the estimated $2.59B. The company also expects its Q1 revenue to decrease by 50% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:04 pm

SMPL

Simply Good Foods anticipates its FY24 sales growth to be at the high end of its long-term target range of 4% to 6%.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:03 pm

MBLY

Mobileye Global Inc. has announced preliminary financial results, projecting FY23 revenue to be between $2.076B and $2.080B, which is in line with the estimated $2.08B. For Q4, the revenue is expected to be between $634M and $638M, also aligning with the estimated $636.59M.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:01 pm

ATRC

AtriCure (NASDAQ:ATRC) was analyzed by 6 analysts, showing a mix of bullish and somewhat bullish ratings with no bearish or indifferent stances. The average 12-month price target is now $52.00, down from $59.00, with a high estimate of $60.00 and a low of $44.00. Analysts from Needham and JMP Securities have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. AtriCure specializes in surgical treatments for atrial fibrillation and related conditions, with a majority of revenue from the U.S. The company has shown strong revenue growth, net margin, ROE, and ROA, with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 12:00 pm

VZ

Seven analysts have recently provided diverse opinions on Verizon Communications (NYSE:VZ), with an average 12-month price target of $42.71, a slight decrease from the previous average. The ratings range from 'Outperform' to 'Equal-Weight', with price targets adjusted accordingly. Verizon's financials show a negative revenue trend, but strong net margin, ROE, and ROA, along with a healthy debt-to-equity ratio. Analysts' ratings are crucial for investors, reflecting expert opinions on stock performance and company prospects.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 12:00 pm

MU

Micron Technology (NASDAQ:MU) has been analyzed by 30 analysts, showing a range of opinions. Recent updates show a positive trend in analyst sentiment, with many raising their price targets. The average 12-month price target is now $93.41, up from $82.21. Micron specializes in memory and storage chips, with a positive revenue growth rate of 15.69% as of November 30, 2023, but faces challenges with a net margin of -26.11% and an ROE of -2.84%. The company's debt-to-equity ratio is healthy at 0.33.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 12:00 pm

MUSA

Murphy USA (NYSE:MUSA) received mixed analyst ratings in the latest quarter, with 1 bullish, 2 somewhat bullish, and 1 bearish rating. Analysts updated their price targets, with an average of $385.00, a high of $425.00, and a low of $280.00, reflecting an 11.38% increase from the previous average target. Corey Tarlowe of Jefferies and Ben Bienvenu of Stephens & Co. raised their targets, while Bonnie Herzog of Goldman Sachs also raised hers but maintains a sell rating. Murphy USA operates gasoline products and convenience stores, mostly adjacent to Walmart stores, and has shown strong financial health with a high ROE and ROA but faces revenue challenges.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 12:00 pm